{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:21:11Z","timestamp":1781875271442,"version":"3.54.5"},"reference-count":19,"publisher":"Bentham Science Publishers Ltd.","issue":"38","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Atopic dermatitis is epidermal hyperplasia, skin barrier dysfunction, and the\naberrant activation of immune cells. Janus kinase (JAK) is a family of cytoplasmic nonreceptor\ntyrosine kinases that consists of four members, such as JAK1, JAK2, JAK3, and\nTYK2. The JAK signaling pathway plays a critical role in a wide range of autoimmune\nand inflammatory diseases, including atopic dermatitis. Abrocitinib is an orally bioavailable\nand selective JAK1 inhibitor, and it was approved in January, 2022, for the treatment\nof atopic dermatitis. The chemical structure and physical properties of abrocitinib, its synthesis,\nmechanism of action, and pharmacokinetic profile are summarized.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867330666230216123419","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T04:07:36Z","timestamp":1676606856000},"page":"4278-4282","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Abrocitinib: First Globally Approved Selective Janus Kinase-1 Inhibitor\nfor the Treatment of Atopic Dermatitis"],"prefix":"10.2174","volume":"30","author":[{"given":"Surya K.","family":"De","sequence":"first","affiliation":[{"name":"Department of Chemistry, Conju-probe, San Diego, CA 92121, California, USA"},{"name":"Department of Chemistry,\nBharath University, Chennai, Tamil Nadu, 600126, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.3390\/jcm11164639","volume":"11","author":"Mastraftsi S.","year":"2022","unstructured":"Mastraftsi S.; Vrioni G.; Bakakis M.; Nicolaidou E.; Rigopoulos D.; Stratigos A.J.; Gregoriou S.; Atopic dermatitis: Striving for reliable biomarkers. J Clin Med 2022,11(16),4639","journal-title":"J Clin Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"St\u00e4nder S.","year":"2021","unstructured":"St\u00e4nder S.; Atopic dermatitis. N Engl J Med 2021,384(12),1136-1143","journal-title":"N Engl J Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3390\/life12081159","volume":"12","author":"Ayen-Rodr\u00edguez A.","year":"2022","unstructured":"Ayen-Rodr\u00edguez A.; Pereyra-Rodr\u00edguez J.J.; Navarro-Trivi\u00f1o F.J.; Alcantara-Luna S.; Dom\u00ednguez-Cruz J.; Gal\u00e1n-Guti\u00e9rrez M.; Vilar-Palomo S.; Armario-Hita J.C.; Ruiz-Villaverde R.; Long-term effectiveness and safety of biologic and small molecule drugs for moderate to severe atopic dermatitis: A systematic review. Life 2022,12(8),1159","journal-title":"Life"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"Reich K.","year":"2022","unstructured":"Reich K.; Thyssen J.P.; Blauvelt A.; Eyerich K.; Soong W.; Rice Z.P.; Hong H.C.; Katoh N.; Valenzuela F.; DiBonaventura M.; Bratt T.A.; Zhang F.; Clibborn C.; Rojo R.; Valdez H.; Kerkmann U.; Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A randomised, double-blind, multicentre phase 3 trial. Lancet 2022,400(10348),273-282","journal-title":"Lancet"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"Gooderham M.J.","year":"2019","unstructured":"Gooderham M.J.; Forman S.B.; Bissonnette R.; Beebe J.S.; Zhang W.; Banfield C.; Zhu L.; Papacharalambous J.; Vincent M.S.; Peeva E.; Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis. JAMA Dermatol 2019,155(12),1371-1379","journal-title":"JAMA Dermatol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"Silverberg J.I.","year":"2020","unstructured":"Silverberg J.I.; Simpson E.L.; Thyssen J.P.; Gooderham M.; Chan G.; Feeney C.; Biswas P.; Valdez H.; DiBonaventura M.; Nduaka C.; Rojo R.; Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis. JAMA Dermatol 2020,156(8),863-873","journal-title":"JAMA Dermatol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"682547","DOI":"10.3389\/fmed.2021.682547","volume":"8","author":"Le M.","year":"2021","unstructured":"Le M.; Berman-Rosa M.; Ghazawi F.M.; Bourcier M.; Fiorillo L.; Gooderham M.; Guenther L.; Hanna S.; Hong H.C.H.; Landells I.; Lansang P.; Marcoux D.; Wiseman M.C.; Yeung J.; Lynde C.; Litvinov I.V.; Systematic review on the efficacy and safety of oral janus kinase inhibitors for the treatment of atopic dermatitis. Front Med 2021,8,682547","journal-title":"Front Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"Bieber T.","year":"2021","unstructured":"Bieber T.; Simpson E.L.; Silverberg J.I.; Tha\u00e7i D.; Paul C.; Pink A.E.; Kataoka Y.; Chu C.Y.; DiBonaventura M.; Rojo R.; Antinew J.; Ionita I.; Sinclair R.; Forman S.; Zdybski J.; Biswas P.; Malhotra B.; Zhang F.; Valdez H.; Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med 2021,384(12),1101-1112","journal-title":"N Engl J Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/1744666X.2021.1828068","volume":"16","author":"Crowley E.L.","year":"2020","unstructured":"Crowley E.L.; Nezamololama N.; Papp K.; Gooderham M.J.; Abrocitinib for the treatment of atopic dermatitis. Expert Rev Clin Immunol 2020,16(10),955-962","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"Simpson E.L.","year":"2020","unstructured":"Simpson E.L.; Sinclair R.; Forman S.; Wollenberg A.; Aschoff R.; Cork M.; Bieber T.; Thyssen J.P.; Yosipovitch G.; Flohr C.; Magnolo N.; Maari C.; Feeney C.; Biswas P.; Tatulych S.; Valdez H.; Rojo R.; Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 2020,396(10246),255-266","journal-title":"Lancet"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","volume":"61","author":"Vazquez M.L.","year":"2018","unstructured":"Vazquez M.L.; Kaila N.; Strohbach J.W.; Trzupek J.D.; Brown M.F.; Flanagan M.E.; Mitton-Fry M.J.; Johnson T.A.; TenBrink R.E.; Arnold E.P.; Basak A.; Heasley S.E.; Kwon S.; Langille J.; Parikh M.D.; Griffin S.H.; Casavant J.M.; Duclos B.A.; Fenwick A.E.; Harris T.M.; Han S.; Caspers N.; Dowty M.E.; Yang X.; Banker M.E.; Hegen M.; Symanowicz P.T.; Li L.; Wang L.; Lin T.H.; Jussif J.; Clark J.D.; Telliez J.B.; Robinson R.P.; Unwalla R.; Identification of N-cis -3-[Methyl(7 H -pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutylpropane-1-sulfonamide (PF-04965842): A selective JAK1 clinical candidate for the treatment of autoimmune diseases. J Med Chem 2018,61(3),1130-1152","journal-title":"J Med Chem"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1021\/acs.oprd.0c00366","volume":"25","author":"Connor C.G.","year":"2021","unstructured":"Connor C.G.; DeForest J.C.; Dietrich P.; Do N.M.; Doyle K.M.; Eisenbeis S.; Greenberg E.; Griffin S.H.; Jones B.P.; Jones K.N.; Karmilowicz M.; Kumar R.; Lewis C.A.; McInturff E.L.; McWilliams J.C.; Mehta R.; Nguyen B.D.; Rane A.M.; Samas B.; Sitter B.J.; Ward H.W.; Webster M.E.; Development of a nitrene-type rearrangement for the commercial route of the JAK1 inhibitor abrocitinib. Org Process Res Dev 2021,25(3),608-615","journal-title":"Org Process Res Dev"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1124\/dmd.122.000829","volume":"50","author":"Bauman J.N.","year":"2022","unstructured":"Bauman J.N.; Doran A.C.; King-Ahmad A.; Sharma R.; Walker G.S.; Lin J.; Lin T.H.; Telliez J.B.; Tripathy S.; Goosen T.C.; Banfield C.; Malhotra B.K.; Dowty M.E.; The pharmacokinetics, metabolism, and clearance mechanisms of abrocitinib, a selective janus kinase inhibitor, in humans. Drug Metab Dispos 2022,50(8),1106-1118","journal-title":"Drug Metab Dispos"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1021\/cr9002193","volume":"110","year":"2010","unstructured":"Hydrocarbon hydroxylation by cytochrome P450 enzymes. Chem Rev Ortiz de M.P.R.2010,110(2),932-948","journal-title":"Chem Rev"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"e2021145","DOI":"10.5826\/dpc.1104a145","volume":"11","author":"Nogueira M.","year":"2021","unstructured":"Nogueira M.; Torres T.; Janus kinase inhibitors for the treatment of atopic dermatitis: Focus on abrocitinib, baricitinib, and upadacitinib. Dermatol Pract Concept 2021,11(4),e2021145","journal-title":"Dermatol Pract Concept"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","volume":"20","author":"He H.","year":"2019","unstructured":"He H.; Guttman-Yassky E.; JAK inhibitors for atopic dermatitis: An update. Am J Clin Dermatol 2019,20(2),181-192","journal-title":"Am J Clin Dermatol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1111\/bcp.13612","volume":"84","author":"Peeva E.","year":"2018","unstructured":"Peeva E.; Hodge M.R.; Kieras E.; Vazquez M.L.; Goteti K.; Tarabar S.G.; Alvey C.W.; Banfield C.; Evaluation of a janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study. Br J Clin Pharmacol 2018,84(8),1776-1788","journal-title":"Br J Clin Pharmacol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1002\/ski2.133","volume":"2022","author":"Lee K.P.","year":"2022","unstructured":"Lee K.P.; Plante J.; Korte J.E.; Elston D.M.; Oral Janus kinase inhibitors in the treatment of atopic dermatitis: A systematic review and meta\u2010analysis. Skin Health Dis 2022,2022,e133","journal-title":"Skin Health Dis"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/ced.14567","volume":"46","author":"Cartron A.M.","year":"2021","unstructured":"Cartron A.M.; Nguyen T.H.; Roh Y.S.; Kwatra M.M.; Kwatra S.G.; Janus kinase inhibitors for atopic dermatitis: A promising treatment modality. Clin Exp Dermatol 2021,46(5),820-824","journal-title":"Clin Exp Dermatol"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230216123419","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/213725\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230216123419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T20:02:59Z","timestamp":1693684979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/213725\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":19,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867330666230216123419","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-09-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}